atropin viatris (atropin mylan) stungulyf, lausn 0,5 mg/ml
viatris limited - atropine sulfate - stungulyf, lausn - 0,5 mg/ml
cordarone tafla 200 mg
sanofi-aventis norge as - amiodaronum hýdróklóríð - tafla - 200 mg
cordarone tafla 100 mg
sanofi-aventis norge as - amiodaronum hýdróklóríð - tafla - 100 mg
eslicarbazepine acetate stada (eslicarbazepine acetate) tafla 800 mg
stada arzneimittel ag - eslicarbazepinum acetat - tafla - 800 mg
eslicarbazepine acetate stada (eslicarbazepine acetate) tafla 200 mg
stada arzneimittel ag - eslicarbazepinum acetat - tafla - 200 mg
baklofen viatris (baklofen mylan) tafla 10 mg
viatris limited - baclofenum inn - tafla - 10 mg
baklofen viatris (baklofen mylan) tafla 25 mg
viatris limited - baclofenum inn - tafla - 25 mg
duspatalin retard hart forðahylki 200 mg
viatris aps - mebeverinum hýdróklóríð - hart forðahylki - 200 mg
tyruko
sandoz gmbh - natalízúmab - multiple sclerosis, relapsing-remitting; multiple sclerosis - Ónæmisbælandi lyf - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 og 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.